A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis - 09/08/11
Doi : 10.1016/j.jaad.2006.02.004
Lorinda Chung, MD a, David Fiorentino, MD, PhD b, ⁎ 
a From the Division of Immunology and Rheumatology
b Department of Dermatology, Stanford University School of Medicine
Correspondence to: David Fiorentino, MD, PhD, Stanford University School of Medicine, Department of Dermatology, 900 Blake Wilbur Dr, Stanford, CA 94305.Stanford, California
Abstract |
We performed a pilot trial of subcutaneous treprostinil for the treatment of digital ulcers in scleroderma. Of the 5 patients completing therapy, ulcer size significantly decreased and no new ulcers occurred on continuous therapy. Although effective, the high rate of injection site reactions may limit the utility of this therapy.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: Medication and partial administrative support was provided by United Therapeutics, Inc. D.F. is partially supported by the Dermatology Foundation Medical Dermatology Career Award and by the Center for Clinical Immunology at Stanford (CCIS) Faculty Scholars Grant. L.C. is partially supported by gift funds from Amgen. Conflicts of interest: D.F. has received consulting and gift funds from United Therapeutics, Inc. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 5
P. 880-882 - mai 2006 Retour au numéro
Article précédent
- April iotaderma (#147)
- Leah Belazarian
- Prolonged survival of angiosarcoma on the nose: A report of 3 cases
- C. William Hanke, J. Barton Sterling
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?